Eric Lawitz

8PUBLICATIONS
14CO-AUTHORS
Medical biochemistry - lipidsMetabolic medicineApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersDiagnostic radiography
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 22, 2026
Liver Biopsy in Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials: Potential Pitfalls and Solutions.

|Dec 09, 2025
Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide.

Husam Albarmawi, Firas Dabbous, Abdalla Aly

|Jan 24, 2025
Effect of Target-Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic Function.

Elise Burmeister Getz, Richard R Stein, Martin Fink

|Jan 31, 2024
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.

Naim Alkhouri, Carl LaCerte, Jeffrey Edwards

|Apr 10, 2020
Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study.

Eric Lawitz, Fred Poordad, Julio A Gutierrez

|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.

Eric Lawitz, Edward Gane, Jordan J Feld

Pageof 2

Frequent Collaborators

2 joint publications

Fred Poordad

1 joint publications

Leen Vijgen

1 joint publications

Veerle Van Eygen

1 joint publications

Naim Alkhouri